Initially, Gastrointestinal Study Group in Japan Clinical Oncology Group (GIOSG/JCOG) focused on gastric cancer. In 1980s, fluoropyrimidine, cisplatin and mitomycin C were key drugs. A randomized Phase II trial (JCOG8501) comparing futrafur plus mitomycin C and uracil plus futrafur and mitomycin C showed a higher response rate of uracil plus futrafur and mitomycin C than futrafur plus mitomycin C. From the results of two Phase II trials of etoposide, adriamycin and cisplatin, and cisplatin plus 5-fluorouracil, uracil plus futrafur and mitomycin C and cisplatin plus 5-fluorouracil were adopted for the test arms of the Phase III trial (JCOG9205) comparing with continuous infusion of 5-fluorouracil as a control arm. Neither cisplatin plus 5-fluorouracil nor uracil plus futrafur and mitomycin C showed a survival benefit over continuous infusion of 5-fluorouracil. In late 1990s, new agents, irinotecan and S-1, were developed for gastric cancer in Japan. GIOSG conducted a Phase III trial (JCOG9912) investigating superiority of irinotecan plus cisplatin and non-inferiority of monotherapy with S-1 compared with continuous infusion of 5-fluorouracil, and S-1 succeeded in showing non-inferiority. Then, SPIRITS trial showed a survival benefit of S-1 plus cisplatin over S-1, resulting in the establishment of a standard care for advanced gastric cancer in Japan. GIOSG have merged with Gastric Cancer Study Group as the Stomach Cancer Study Group (SCSG) from 2011. Recent progress in the development of new drugs has been remarkable. From the point of the roles shared with many other study groups for clinical trials, including registration trials of new drugs conducted by pharmaceutical companies, SCSG should recognize its role and conduct clinical trials with high quality for establishing new standard treatment.
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INTRODUCTION
In Japan, there are several clinical trial groups. Japan Clinical Oncology Group (JCOG) is a clinical study group in which many multi-institutional clinical trials have been conducted mainly by the support of research aid from the Ministry of Health, Labour and Welfare in Japan. While Oncology Group (WJOG), Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG), Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC), Kyushu Study Group of Clinical Cancer (KSCC), etc. have also been contributing to establish new evidences for gastrointestinal malignancy, the Gastrointestinal Oncology Study Group (GIOSG) was one of the oldest three study groups dedicated to medical oncology at the beginning of JCOG and has been conducting clinical trials of gastrointestinal malignancy. Table 1 shows the summary of clinical trials conducted by GIOSG (1 -20) . In late 1980s, GIOSG focused on gastric cancer and conducted a several Phase II trials (1 -4) . In early 1990s, it could launch the first Phase III trial (JCOG9205) (5), although its sample size was small. And then, GIOSG could complete a large Phase III trial (JCOG9912) (13) . In the twenty-first century, GIOSG challenged to difficult clinical trials [JCOG0106 (14) and 0407 (15) ] for gastric cancer patients with severe peritoneal metastasis, who are usually excluded from clinical trials especially for new drug approval, meaning that new standard treatment, including new agents, can hardly be applied to these patients. Along with these clinical trials, GIOSG has been continuing to conduct translational researches to find predictive marker for chemotherapy effects using the archived tissues of the patients enrolled to JCOG9001 (21), 9205 (22) and 9912 (23, 24) . Recently, GIOSG has expanded its activity for colorectal cancer [JCOG9703 (9) 
1316
Past and present achievements, and future direction of GIOSG in JCOG (JCOG0604) of S-1 for approval to esophageal cancer. Completion of these clinical trials leads to the establishment of new study groups such as the Hepatobiliary and the Pancreatic Oncology Group, the Gastrointestinal Endoscopy Study Group and the Head and Neck Cancer Study Group in JCOG. GIOSG has merged with Gastric Cancer Study Group as the Stomach Cancer Study Group (SCSG) from 2011. This paper reviews the history of GIOSG, introduces the present activity and proposes the future direction mainly in the field of gastric cancer (Fig. 1) .
DAWN OF GIOSG
Till early 1990s, all of GIOSG trials (1 -4) were Phase II. In those days, several oral fluoropyrimidines were developed and cisplatin (CDDP) was approved for gastric cancer in Japan. In the randomized Phase II study [JCOG8501 (1)] comparing futrafur plus mitomycin C (MMC) (FTM) with uracil and futrafur plus MMC (UFTM), UFTM showed a higher response rate (25%, n ¼ 79) than FTM (8%, n ¼ 90). In JCOG8804 (2), 5 0 -deoxy-5-fluorouridine (5 0 DFUR) plus CDDP showed a response rate of 50% in 28 patients with measurable lesion. In the Phase II trial [JCOG8903 (3)] of EAP, combination of etoposide, adriamycin (ADM) and CDDP, despite a high response rate and 5-year survival of 10%, treatment-related deaths occurred in 10%. While the dose and schedule of combination of 5-fluorouracil (5-FU) and CDDP (FP) in JCOG9001 (4) were modified from those in Western trials, it showed a response rate (43%, n ¼ 40) and survival similar to those of Western trials. From these results, GIOSG concluded that FP and/or UFTM would be selected as test arms for the future Phase III trial.
JCOG9205
It was reported that combination chemotherapy consisting of 5-FU, ADM, and MMC did not show a survival advantage over 5-FU alone (25) . Consequently, GIOSG conducted a three-arm Phase III [JCOG9205 (5)] trial comparing FP and UFTM with continuous infusion of 5-FU (5-FUci). As a Jpn Table 2) , 280 patients were accrued for 4.5 years, and FP did not show significantly longer survival despite its higher response rate and longer progression-free survival, associated with more severe toxicities than 5-FUci. After intensive discussion about which regimen should be adopted for a control arm in the future trial, FP (global standard) or 5-FUci (winner in JCOG9205), it was concluded that 5-FUci would be a reference arm in the next Phase III trial from the point of overall survival (true endpoint of clinical trials).
JCOG9912
In late 1990s, new anti-tumor agents such as S-1, irinotecan (CPT-11), paclitaxel (PTX) and docetaxel (DTX) were developed and approved for gastric cancer in Japan. From the promising results of Phase II trials of CPT-11 plus CDDP (26) and S-1 (27, 28) , GIOSG planned a three-arm Phase III study [JCOG9912 (13) ] to investigate superiority of CPT-11 plus CDDP and non-inferiority of S-1 compared with 5-FUci with the primary endpoint of overall survival. Seven hundred and four patients were accrued for 5 years. Table 3 Additional analysis, 2 years after last patient accrual in May 2008, showed that CPT-11 plus CDDP showed an HR of 0.82 (95% CI 0.68 -0.99, P ¼ 0.0194), while an HR of S-1 was 0.83 (95% CI 0.68 -1.00, P ¼ 0.0233 for superiority). In conclusion, S-1 should be considered for the standard chemotherapy of advanced gastric cancer. Thus, S-1 can also replace 5-FUci. Based on the results of JCOG9912, SPIRITS (29) trial, conducted by a pharmaceutical company, which compared S-1 plus CDDP with S-1 showed a survival benefit of S-1 plus CDDP over S-1, leading to the establishment of a standard care for advanced gastric cancer in Japan.
From the present point of view, the quality of JCOG9205 was not so good as the recent clinical trials, JCOG9912 and thereafter, lacking in (i) peer review system of protocol drafts, (ii) central monitoring of case report forms by the data center and a trial office, and (iii) feedback to each investigator. The greatest problem was the speed of patient accrual. While 280 patients were enrolled for about 4.5 years (five patients monthly) in JCOG9205, 704 were for about 6 years (10 patients monthly) in JCOG9912. Actually, JCOG9912 was completed without major violation, including only one ineligible case. It can be said that the quality of the clinical trial in GIOSG was surely improved during JCOG9912.
TRANSLATIONAL RESEARCH
Personalized medicine is one of most important treatment strategies for advanced gastric cancer patients treated with not only molecular target agents but cytotoxic agents because gastric cancer shows very heterogeneous behaviors. GIOSG challenged to a translational research to find predictive marker for chemotherapy effects using the archived tissues of the patients enrolled to JCOG9001 (21), 9205 (22) and 9912 (23, 24) . The methods of evaluating chemosensitivity-related factors were initially limited to immunohistochemistry using formalin-fixed samples in JCOG9001 and 9205, and recently have progressed to lasercaptured microdissection and real-time RT -PCR in JCOG9912. The explorative study along with a Phase II trial of FP (JCOG9001) showed that the number of favorable phenotypes out of five chemosensitivity factors, p53(2), bcl-2(2), vascular endothelial growth factor (VEGF)(þ), glutathione S-transferase p(2) and thymidylate synthase(2), was a prognostic factor (21) , and this result was recapitulated in the confirmative translational study of JCOG 9912 in which pretreatment biopsy were available in 131 of 210 (62%) patients allocated to 5-FUci or FP in the JCOG9205 trial (22) . And it was also shown that FP showed a longer survival than 5-FUci among the VEGF(þ) patients, while there was no difference in overall survival between the two arms among the VEGF(2) patients. These results suggested that multiple factors may be implicated to chemosensitivity and personalized medicine should be investigated in randomized trials. Then, pretreatment tumor tissue was available from 365 of 704 (52%) patients enrolled in JCOG9912 trial. It was suggested that dihydropyrimidine dehydrogenase might be a selective marker between CPT-11 plus CDDP and S-1 (23) and excision repair cross-complementing group 1 may be an independent prognostic factor for overall survival after first-line treatment of advanced gastric cancer (24) .
COMBINED ANALYSIS OF JCOG9205 AND 9912
While both JCOG9205 (5) and 9912 (13) trials contained 5-FUci as control arms, their median overall survivals were 7.1 months in JCOG9205 and 10.8 months in JCOG9912. While about half of the patients received the second-line chemotherapy in JCOG9205, more than 70% of the patients did in JCOG9912. It is speculated that the second-line chemotherapy might contribute to prolongation of advanced gastric cancer patients. After harmonizing the inclusion criteria of both trials and adjusting patient backgrounds, while time to treatment failure was almost similar (hard ratio, 0.95), overall survival (OS) and survival after treatment failure (OS-TTF) were better in JCOG9912 than JCOG9205 (HR; OS 0.71, 95% CI 0.56 -0.99, OS-TTF 0.72, 95% CI 0.57 -1.01) (30) . Although survival benefit of the secondline chemotherapy for advanced gastric cancer has not been confirmed by randomized Phase III trials, these results suggest that the second-line chemotherapy with new agents approved in late 1990s such as CPT-11, PTX, and DTX might have contributed to the prolongation of the OS because there were no active drug for the second-line chemotherapy in the era of JCOG9205.
JCOG0106 AND 0407
Peritoneum is one of the common metastatic sites as well as liver and lymph nodes. The incidence of peritoneal metastasis is higher than 50% among patients with advanced gastric cancer. The prognosis of patients with severe peritoneal metastasis is considered to be poor because it causes various complications such as ascites, bowel obstruction and hydronephrosis, and deteriorates patient's general condition. Moreover, these patients usually do not have target lesions according to RECIST. For these reasons, patients with severe peritoneal metastasis are usually excluded from clinical trials. Thus, evidence from clinical trials can hardly be applied to these patients and the standard chemotherapy for them has not been established. GIOSG challenged to the Phase III trial [JCOG0106 (14)] targeting to the patients with severe peritoneal metastasis, comparing sequential therapy of 5-FU and methotrexate (MTX) (MF) based on the results of JCOG9603 (8) , in which massive ascites remarkably decreased in 13 out of 37 patients (35%) by MF therapy. In JCOG0106, a total of 237 patients were enrolled for 4.5 years, and MF could not show a survival benefit over 5-FUci [median survival time (MST); 5-FUci/MF 9.4/10.6 months, HR 0.94, 95% CI 0.72 -1.22,
Although not a few patients are complicated with severe peritoneal metastasis after failure in the first-line chemotherapy, the second-line chemotherapy is limited by patient's poor condition. Thus, GIOSG conducted a randomized Phase II trial [JCOG0407 (16) ] comparing best available 5-FU with weekly administration of PTX for the patients with severe peritoneal metastasis in the second-line chemotherapy after failure in the first-line chemotherapy containing fluoropyrimidine. MST in each arm was the same, 7.7 months, and survival at 1 year was 31.4% in weekly PTX and 27.1% in best available 5-FU (HR ¼ 0.887, 95% CI 0.571 -1.377, P ¼ 0.298), associated with less toxicity of PTX. Thus, JCOG0407 suggested activity and feasibility of weekly PTX for gastric cancer patients with severe peritoneal metastasis in the second line.
AT PRESENT
In 2006, Japanese guideline changed and requires a Phase III trial for approval of new anti-cancer agents. Before JCOG9912, new agents such as CPT-11 and S-1 had been approved only after completing Phase II trials, and JCOG could run a Phase III trial using these new agents to investigate survival benefit of these new drugs. Top 5 of 37 institutions in GIOSG enrolled more than half of the patients of JCOG9912, and top 10 institutions covered two-thirds of all. After JCOG9912, many industry-sponsored registration Phase III trials of new molecular target agents, such as trastuzumab, bevacizumab and cetuximab in the first line and lapatinib and everolimus in the second line, have been conducted globally, and some of top institutions with high activity in GIOSG have participated to them. This means leading institutions of GIOSG have contributed to both JCOG and registration trials. However, it was difficult to participate simultaneously both in JCOG trials and to registration trials, and actually there has been no clinical trial of chemotherapy for advanced gastric cancer since completion of JCOG0407 in 2008.
At present, GIOSG has been planning two Phase III trials. One is a trial of triplet chemotherapy which may cause severe hematological toxicity, investigating additional effects of DTX on S-1 plus CDDP, accompanied by translational research for personalized medicine. The other trial focuses on poor conditioned patients who cannot take even oral drugs or receive large volume hydration due to severe peritoneal metastasis with/without ascites, comparing weekly PTX Figure 2 .
Step and role for progress in new drug development. 
FUTURE DIRECTION
It is well known that many steps from basic reach to Phase III trial for new drug approval. Furthermore, optimization of new drug is necessary to obtain better outcome in clinical practice such as multimodality treatment, treatment strategy covering all through clinical course and personalized medicine. All these steps are very important for progress in cancer treatment (Fig. 2) . From the point of the roles shared with many other clinical trial groups, and pharmaceutical companies which are the main promoters of new drugs development, SCSG should recognize its own role. It is considered that the most important role of SCSG is to conduct a post-market trial for establishing new standard treatment in clinical practice, containing multimodality treatments, translational research, second-line chemotherapy and personalized medicine. Especially, because the recent indication of new drugs has been limited for 'unresectable or recurrent disease' and not for perioperative setting of resectable disease, SCSG consisting of both medical oncologist and surgeons should collaborate to conduct an investigator-initiated Phase III trial for expanding the indication of new drugs to perioperative chemotherapy (e.g. herceptin in the adjuvant setting for Her-2-positive gastric cancer) in the near future. Finally, the future trials should be large scale and focus on optimization of new drugs in multimodality treatments. Thus, collaboration with the other clinical trial groups, pharmaceutical companies and government, not only in Japan but in the global, will be dispensable. In conclusion, SCSG should make efforts to conduct clinical trials with high quality for new standard treatment.
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